12:15 – 1:15 pm Friday, September 4

High Risk Neuroblastoma in the new decade: Incorporating targeted therapies to maximize impact in current Children’s Oncology Group trials (C226)

While the overall cure rate for childhood cancer is approaching 80%, the prognosis for long-term survival for children with high risk neuroblastoma lags considerably behind, at 50%–60%. Upfront standard treatment for high-risk neuroblastoma protocols within the Children’s Oncology Group (COG) has historically utilized all available modalities of cancer treatment including chemotherapy, surgery, myeloablative chemotherapy with stem cell rescue, radiation therapy, differentiating agents, and most recently biologic therapy with anti-GD2 antibody (dinutuximab) used post consolidation in ANBL0032.

Read more...
Speaker:

Wendy Fitzgerald, MSN APRN PPCNP-BC

Denise Mills, MN RN(EC) NP CPHON®

CNE Hours
1
Subscribe to this RSS feed